Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US approval for Innovative Technologies' alginate dressings

This article was originally published in Clinica

Executive Summary

UK-based biomaterials developer Innovative Technologies Group has received 510(k) clearance from the US FDA for a range of alginate dressings. The clearance took a mere 17 days and adds alginate dressings to Innovative's approved film and hydrocolloid dressings for sale in the US. The company estimates the US alginate dressings market at about $25 million a year, growing by 25% a year.

You may also be interested in...



Amneal Takes Control Of AvKARE In US

Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”

New EU Commissioner Outlines Plans To Tackle Shortages

The EU’s new health commissioner, Stella Kyriakides, has outlined the commission’s plans for dealing with medicines access issues in the EU member states. They include completing the review of the EU pediatric and orphan legislation and developing a new strategic plan to tackle shortages and affordability problems next year.

Execs On The Move: Owens & Minor And MicroPort See Big Departures; Dynatronics CEO Moving To BrainsWay

Owens & Minor finance boss joins drug-delivery device maker Intersect ENT; operations VP at MicroPort joins bioprosthetic heart maker Carmat; Dynatronics CEO will head neuromodulation product firm BrainsWay in January; and more.

Topics

UsernamePublicRestriction

Register

MT093589

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel